Clearside Biomedical to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Tuesday, November 10, 2020
Clearside Biomedical (NASDAQ:CLSD) will report its third quarter 2020 financial results on November 10, 2020, after market close. A webcast and conference call are scheduled for 4:30 PM ET for discussions on these results and corporate updates. Clearside specializes in treatments aimed at restoring vision for patients with serious eye diseases, utilizing a flexible, non-surgical SCS Microinjector® to deliver targeted therapies.
- Scheduled release of Q3 2020 financial results may reflect positive growth metrics.
- Planned webcast indicates transparency and engagement with investors.
- None.
ALPHARETTA, Ga., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its third quarter 2020 financial results will be reported on Tuesday, November 10, 2020 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing (844) 263-8310 (domestic) or (213) 358-0959 (international) and entering conference code: 3169417.
About Clearside Biomedical
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside’s proprietary SCS Microinjector® targets the suprachoroidal space (SCS®) and offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications, as well as future therapeutic innovations such as gene therapy. For more information, please visit www.clearsidebio.com.
Investor and Media Contacts:
Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206
Source: Clearside Biomedical, Inc.
FAQ
What date will Clearside Biomedical release its Q3 2020 financial results?
What is the focus of Clearside Biomedical's treatments?
When is the conference call to discuss Clearside's financial results?
How can I access the Clearside Biomedical conference call?
